title: Case report of a kidney transplant recipient converted to everolimus due to malignancy: resolution of bronchiolitis obliterans organizing pneumonia without everolimus discontinuation.
abstract: The use of proliferative signal inhibitors (PSIs) in immunosuppression-related malignancies opens new roads for increasing the survival and quality of life in patients with solid organ transplantation. A 56-year-old female recipient of a living donor renal allograft (1990), who was immunosuppressed with cyclosporine (CsA; Neoral), azathioprine, and steroids, did initially well with acceptable renal function. During the last 5 years she required local therapy due to posterior vaginal lip human papillomavirus (HPV) lesions. In 2000, she discontinued azathioprine and the CsA doses were reduced to 100 mg daily. The local lesion showed a good response to reduced immunosuppression. In February 2005, the lesion reappeared and a biopsy showed malignancy. Local surgery was performed and CsA was replaced by everolimus (EVL; Certican). Two months after treatment initiation, the patient developed cough, dyspnea, and low-grade fever. Chest X-ray showed a lesion at the base of the left lung compatible with pneumonitis. After fiberbronchoscopy a diagnosis of bronchiolitis obliterans organizing pneumonia (BOOP) was obtained. She was treated with increased doses of oral steroids. EVL was never discontinued. The radiological lesion disappeared and the malignancy is currently in remission. In summary, a case of gynecological cancer in a renal transplant recipient was treated by surgical removal. After 1 year of immunosuppression with EVL, no recurrence has been observed. The adverse event (BOOP) was probably related to the PSI treatment and was controlled with an increased dose of steroids without discontinuing EVL.
authors: Hospital Aeronáutico Central, Buenos Aires, Argentina. cesarac@fibertel.com.ar
authors: C Agost
authors: CA
authors: Carreño
authors: M
authors: M
authors: Gadea
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use; D018549:Cryptogenic Organizing Pneumonia / Q000188:drug therapy; D016572:Cyclosporine / Q000627:therapeutic use; D000068338:Everolimus; D005260:Female; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology*; D008775:Methylprednisolone / Q000627:therapeutic use; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000175:diagnosis; D007690:Polycystic Kidney Diseases / Q000601:surgery; D011183:Postoperative Complications; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014625:Vaginal Neoplasms / Q000601:surgery
chemical_list: D000305:Adrenal Cortex Hormones; D016572:Cyclosporine; D000068338:Everolimus; D001379:Azathioprine; D020123:Sirolimus; D008775:Methylprednisolone